Restoring the pyrimidine metabolism pathway via Sodium‐glucose cotransporter 2 (SGLT2) inhibitors could alleviate hepatic changes in nonalcoholic fatty liver disease [39]. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.